GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Handled COVID very well. Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. Contact Email info@immunic.de. We are based at the Translation & Innovation Hub that sits on Imperial College London's 23-acre White City Campus development in west . The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. CONTACT US. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). Immunomic Therapeutics Assumes Sponsorship of ATTAC II IND - Duke OTC AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Immunic Therapeutics Company Profile: Stock Performance & Earnings For more information, please visit www.immunomix.com. All content is posted anonymously by employees working at Immunomic Therapeutics. Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Innovative Cellular Therapeutics (ICT) | LinkedIn ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Immunomic Therapeutics - Products, Competitors, Financials, Employees Please include the Job Code in the subject line and attach a cover letter and salary requirement along with a current resume to complete your candidacy submission for each position in which you are interested. DC Inno - Exclusive: Rockville biotech expanding, 'on the prowl' for San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Pipeline - Immunomic Therapeutics ImmunoMet Therapeutics - Crunchbase Company Profile & Funding
